Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo
Progression‐free survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Palifermin showed no clear difference in progression-free survival compared with placebo; GRADE not reported.
1 finding from 1 review
- Pharmacological interventions for preventing dry mouth and salivary gland dysfunction following radiotherapy 2017 · Cochrane All outcomes42 to 72 months from baselineHR 1.06 [0.80, 1.42]3 studiesGRADE not reported